Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907

por Østergaard, Helena Bleken, van der Leeuw, Joep, Visseren, Frank L.J., Westerink, Jan
Publicado 2021

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

por Østergaard, Helena Bleken, Humphreys, Valerie, Hengeveld, Ellen Margo, Honoré, Julie Broe, Mach, François, Visseren, Frank L. J., Westerink, Jan, Yadav, Gourav, Mosenzon, Ofri
Publicado 2022

Lifestyle changes and kidney function: A 10‐year follow‐up study in patients with manifest cardiovascular disease

por Østergaard, Helena Bleken, Demirhan, Imre, Westerink, Jan, Verhaar, Marianne C., Asselbergs, Folkert W., de Borst, Gert J., Kappelle, L. Jaap, Visseren, Frank L. J., van der Leeuw, Joep
Publicado 2022

End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study

por Østergaard, Helena Bleken, Westerink, Jan, Verhaar, Marianne C., Bots, Michiel L., Asselbergs, Folkert W., de Borst, Gert J., Kappelle, L. Jaap, Visseren, Frank L. J., van der Leeuw, Joep
Publicado 2021